Antengene Corporation Limited (HK:6996) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Antengene Corporation Limited has received approval from South Korea’s Ministry of Food and Drug Safety for a supplemental New Drug Application for XPOVIO, marking its third indication. This approval allows the use of XPOVIO in combination with other drugs to treat multiple myeloma, further strengthening Antengene’s position in the global biopharmaceutical market. The company is known for its innovative treatments targeting hematologic malignancies and solid tumors.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.
